Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetic Neuropathy

In brief

The purpose of this protocol is to investigate the safety, tolerability and effectiveness of CAST as a treatment for diabetic neuropathy. The primary outcome measure will be Total Neuropathic Symptom Score. Secondary outcomes will be neurological disability score, nerve conduction measurements and quantitative sensory testing. Statistical analyses will compare changes from baseline for CAST- and placebo-treated groups at both time points, compare effects of CAST at 6 and 12 months and, if numbers permit, compare doses.

Key facts

Study ID

NCT00608439

Run by

Oregon Health and Science University

People needed

43

Starts

2007-09-01

Expected to finish

2011-08-01

Last updated by the study team

2012-11-12

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type II diabetes that is being treated with diet, oral antidiabetic agents and/or insulin
• stable glycemic control over the last 3 months
• evidence of symptomatic symmetrical distal neuropathy
• total symptom score of 4 or more
• stable HbA1c level of less than 8.5 over last three months

You may not qualify if…

• Smokers
• Asymmetrical neuropathy of the trunk and proximal lower limbs
• Presence of foot ulcers
• Peripheral vascular disease (non-palpable foot pulses, intermittent claudication)
• Myopathy
• Causes of neuropathy other than diabetes
• Participation in a study of any investigational drug for diabetic neuropathy within 3 months of the study
• Use of any other product containing CA in the last 3 months
• Starting to use antioxidants or Vitamin B within 1 month before the study
• Severe concomitant diseases including neurological disease
• Pregnancy, lactation or being of child-bearing age without birth control
• HBA1c level higher than 8.5
• Use of any experimental drugs in the three months prior to start of the study
• Use of anti-coagulant therapy (heparin or coumarin based drugs)
• A QTc of more than 500 ms at baseline ECG
• Uncontrollable hypertension, defined as diastolic pressure greater than 110, and systolic pressure greater than 160

Where it is running

• Oregon Health and Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.